APP and Alzheimer disease: Early models expressing human Aβ fragments, wild type human APP, or fusion proteins containing the C-terminal fragment of wild type APP or Aβ42 showed little or sparse AD-like neuropathology or atypical Aβ deposition (Philipson et al., 2010).